staurosporine has been researched along with gw-5074 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Amin, S; Jaiswal, AS; Law, BK; Narayan, S; Ramisetti, S; Sharma, AK; Singh, P; Singh-Pillay, A | 1 |
| Bang, EK; El-Damasy, AK; Jin, H; Keum, G; Seo, SH | 1 |
| He, S; Ji, Y; Lin, Y; Ma, H; Tian, S; Wu, S; Xia, K; Xu, C; Zhang, X; Zhu, F | 1 |
3 other study(ies) available for staurosporine and gw-5074
| Article | Year |
|---|---|
ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
Topics: Adamantane; Antineoplastic Agents; Aza Compounds; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Molecular Structure; Oxaliplatin; Stem Cells; Structure-Activity Relationship; Tumor Cells, Cultured | 2019 |
Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity.
Topics: Amination; Antineoplastic Agents; Cell Proliferation; Drug Design; Fusion Proteins, bcr-abl; Humans; Indazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Docking Simulation; Protein Kinase Inhibitors | 2020 |
Ring closure strategy leads to potent RIPK3 inhibitors.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Proliferation; Cell Survival; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Hypothermia; Injections, Intravenous; Mice; Mice, Inbred C57BL; Molecular Structure; Protein Kinase Inhibitors; Receptor-Interacting Protein Serine-Threonine Kinases; Structure-Activity Relationship; Systemic Inflammatory Response Syndrome; Tumor Necrosis Factor-alpha | 2021 |